导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 8.34% | 942/4773 |
| 近一周 | -1.39% | 2118/5465 |
| 近一月 | -4.42% | 3232/5421 |
| 近一季 | -12.80% | 4067/5231 |
| 近半年 | 1.09% | 1218/4920 |
| 近一年 | 12.75% | 930/4394 |
| 近两年 | 91.73% | 706/2954 |
| 近三年 | 43.61% | 678/2253 |
| 成立以来 | 44.32% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-0.91% 2014/4961 |
26.52% 1026/5312 |
- - |
- - |
| 2025 | 29.18% 1420/4813 |
6.02% 690/3635 |
2.60% 1472/4076 |
14.38% 2913/4524 |
3.82% 614/4813 |
| 2024 | 0.64% 2055/3463 |
-12.22% 2451/2808 |
-8.10% 2168/3014 |
21.96% 522/3129 |
2.30% 963/3463 |
| 2023 | 3.68% 267/2656 |
16.85% 189/2280 |
-0.67% 399/2385 |
-10.79% 2022/2515 |
0.13% 164/2655 |
| 2022 | -25.73% 1342/2207 |
-18.41% 1334/1919 |
1.02% 1510/2016 |
-14.42% 1090/2113 |
5.29% 475/2208 |
| 2021 | 26.89% 93/1822 |
-11.20% 1130/1255 |
23.56% 115/1330 |
3.06% 420/1466 |
12.22% 82/1822 |
| 2020 | - - |
- - |
4.04% 918/1067 |
5.69% 899/1164 |
-3.61% 1131/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 港股医疗ETF | 1.4546 | 31.90% |
| 华富中证港股通创新药指数型发起式A | 1.1637 | 30.96% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.3128 | 30.52% |
| 中欧中证港股通创新药指数发起A | 1.6103 | 30.52% |
| 嘉实中证港股通创新药指数发起式C | 0.8566 | 30.50% |
| 中欧中证港股通创新药指数发起C | 1.4583 | 30.44% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8927 | 30.26% |
| 景顺长城中证港股通创新药ETF联接C | 1.4696 | 29.97% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8736 | 29.94% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8719 | 29.88% |
| 国寿创精选88ETF联接A VS. 长安沪深300非周期A(740101) |